A detailed history of Bessemer Group Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 4,842 shares of EXEL stock, worth $159,204. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,842
Previous 466 939.06%
Holding current value
$159,204
Previous $10,000 1160.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$21.96 - $27.6 $96,096 - $120,777
4,376 Added 939.06%
4,842 $126,000
Q1 2024

May 13, 2024

SELL
$20.17 - $23.93 $201 - $239
-10 Reduced 2.1%
466 $11,000
Q3 2023

Nov 13, 2023

SELL
$19.04 - $22.74 $799 - $955
-42 Reduced 8.11%
476 $11,000
Q2 2023

Aug 10, 2023

BUY
$18.17 - $20.48 $4,905 - $5,529
270 Added 108.87%
518 $10,000
Q1 2023

May 10, 2023

BUY
$16.3 - $19.41 $896 - $1,067
55 Added 28.5%
248 $5,000
Q4 2022

Feb 13, 2023

SELL
$14.96 - $17.39 $374 - $434
-25 Reduced 11.47%
193 $3,000
Q3 2022

Nov 09, 2022

BUY
$15.68 - $22.27 $3,026 - $4,298
193 Added 772.0%
218 $3,000
Q2 2022

Aug 10, 2022

BUY
$17.44 - $23.16 $436 - $579
25 New
25 $1,000
Q4 2019

Feb 04, 2020

SELL
$15.15 - $18.89 $19,816 - $24,708
-1,308 Closed
0 $0
Q2 2019

Jul 19, 2019

BUY
$18.93 - $24.75 $24,760 - $32,373
1,308 New
1,308 $28,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.6B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.